Provided by Tiger Trade Technology Pte. Ltd.

Edwards Lifesciences

85.78
-0.7000-0.81%
Post-market: 85.780.00000.00%19:59 EDT
Volume:3.51M
Turnover:302.08M
Market Cap:49.46B
PE:49.90
High:87.30
Open:86.65
Low:85.49
Close:86.48
52wk High:96.29
52wk Low:72.30
Shares:576.54M
Float Shares:575.03M
Volume Ratio:1.03
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.72
EPS(LYR):1.83
ROE:9.18%
ROA:8.37%
PB:4.66
PE(LYR):46.80

Loading ...

Edwards Lifesciences Price Target Announced at $110.00/Share by Barclays

Dow Jones
·
Yesterday

Press Release: Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026

Dow Jones
·
Yesterday

Barclays Remains a Buy on Edwards Lifesciences (EW)

TIPRANKS
·
Yesterday

Edwards Lifesciences initiated with an Overweight at Barclays

TIPRANKS
·
Yesterday

Edwards Lifesciences Corp. Stock Underperforms Monday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Oct 06

Evercore ISI Adjusts Price Target on Edwards Lifesciences to $102 From $100, Keeps Outperform Rating

MT Newswires Live
·
Oct 05

Edwards Lifesciences to Host Investor Event Alongside TCT Symposium Webcast

Reuters
·
Oct 05

Edwards Lifesciences (EW) Receives a Buy from RBC Capital

TIPRANKS
·
Oct 03

Edwards Lifesciences Receives FDA Approval for Autus Valve, the First Surgical Pulmonary Valve for Pediatric Patients

THOMSON REUTERS
·
Oct 02

US FDA - Approves Autus Size-Adjustable Valve for Pediatric Congenital Pulmonary Valve Disease

THOMSON REUTERS
·
Oct 02

US FDA - Edwards Lifesciences Receives FDA Approval for Autus Size-Adjustable Valve

THOMSON REUTERS
·
Oct 02

Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 01

Edwards Lifesciences' TAVR Evaluation in Moderate Aortic Stenosis Among Most Awaited Clinical Trial Readouts, Oppenheimer Says

MT Newswires Live
·
Sep 30

Leerink Partners Sticks to Their Buy Rating for Edwards Lifesciences (EW)

TIPRANKS
·
Sep 29

Edwards Lifesciences Corp. Stock Advances 4.1%, Outperforms Peers

Dow Jones
·
Sep 17

Movement Alert|Edwards Lifesciences Rises 3.08% in Regular Trading, Medicare TAVR Coverage Decision and Guidance Reaffirmation Boost Sentiment

Market Focus
·
Sep 16

Edwards Lifesciences CVP, TAVR Daniel J. Lippis Disposes of 619 Common Shares Worth $54,168.69

Reuters
·
Sep 12

Edwards Lifesciences Corp. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 12

Edwards Lifesciences Price Target Maintained with a $110.00/Share by BTIG

Dow Jones
·
Sep 11

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Labcorp Holdings (LH) and Edwards Lifesciences (EW)

TIPRANKS
·
Sep 11